Pharmaceutical GMP • Digital Quality • Model Lifecycle

AI and Machine Learning Validation in Pharma: A GMP Lifecycle Guide

A practical, risk-based guide to assessing AI and machine learning for pharmaceutical development, manufacturing, laboratories, and quality operations—from intended use and data controls to model testing, monitoring, and change management.

WEBOFPHARMA.COM

AI validation in pharma GMP lifecycle control Updated: October 2026

Artificial intelligence and machine learning can help pharmaceutical teams interpret process data, detect anomalies, prioritize investigations, forecast equipment needs, and support scientific decisions. When an AI-enabled system is used for a regulated activity, the company still needs evidence that the system is fit for its intended use and remains controlled as the software, data, process, and operating environment change.

Quick answer: How do you validate AI and machine learning in pharma?

Start by defining the model’s intended use and the decisions it can influence. Assess the risk to patient safety, product quality, and data integrity; establish acceptance criteria before testing; verify data provenance and representativeness; challenge the model with independent, realistic test data; document the software and model configuration; and monitor performance after release. Apply controlled change management to retraining, updates, thresholds, integrations, and new use cases. Keep a qualified person accountable for decisions that affect GMP disposition unless the process and system are specifically designed, validated, and approved for that level of automation.

Key takeaways

• There is no single universal “AI validation certificate.” Validation is tied to a defined model, system configuration, intended use, users, data, and process.
• Use risk management to scale the evidence and controls to the possible impact on product quality, patient safety, and data integrity.
• Model testing should be independent of training and tuning; document data selection, labeling, exclusions, limitations, and performance by relevant subgroups or operating conditions.
• Deployment does not finish validation. Trend real-world performance, investigate drift and overrides, and control model or platform changes.
• As of October 2, 2026, the EU AI Annex 22 material for GMP manufacturing is a consultation draft, not a published effective annex. FDA’s 2025 AI credibility guidance for drug submissions is also draft, and the 2023 manufacturing paper is a discussion paper.

Regulatory status check — October 2, 2026: The European Commission’s current EudraLex index lists the published Annex 11 revision as January 2011. The Commission’s consultation on a revised Annex 11 and new Annex 22, Artificial Intelligence, has closed; the draft Annex 22 proposes additional controls for certain critical, static, deterministic machine-learning models used in GMP manufacturing. Do not treat draft text as an effective requirement until the Commission formally publishes and applies a final version. In the United States, FDA’s January 2025 AI guidance is a draft focused on AI-generated information or data used to support regulatory decisions on drug and biological products. FDA’s 2023 AI in Drug Manufacturing paper is expressly for discussion, not draft or final guidance. Always verify the live regulator page before updating a site procedure.

Define the useSpecify the question the model answers, its users, boundaries, and the decisions that may rely on it.

Test the evidenceUse fit-for-purpose data and criteria that show whether the model works in its real operating context.

Control the lifecycleManage deployment, monitoring, incidents, changes, retraining, retirement, and retained records.

What does AI validation mean in a pharmaceutical setting?

AI validation is the documented demonstration that an AI-enabled application performs its defined function consistently enough for its intended use, with appropriate controls over the full lifecycle. It includes more than checking whether a model produces plausible answers. The regulated system may include data sources, preprocessing code, the model, prompts or rules, interfaces, infrastructure, user permissions, review steps, and records of decisions.

Machine learning systems infer patterns from data rather than relying only on explicitly coded rules. Two models can have very different risk profiles: a tool that groups historical maintenance tickets for search is not equivalent to one that flags a batch for quality review or calculates a value used in a manufacturing control loop. The validation scope follows the actual use and reliance, not the marketing label “AI.”

For a broader foundation, connect the assessment to your site’s Computerized System Validation lifecycle and applicable cGMP procedures. If the system creates, transforms, or stores regulated records, assess data integrity and electronic-record controls, including applicable 21 CFR requirements.

Where can AI and machine learning be used in pharma?

Potential applications range from low-impact administrative support to systems that affect a critical quality decision. Examples below are illustrative; the same tool can have a different risk classification at different sites depending on its intended use and how people rely on its output.

Potential use	Example output	Validation questions
Process monitoring	Detects unusual trends in temperature, pressure, flow, or other process data.	Are sensors and timestamps reliable? What constitutes an actionable alert? Could missed or false alerts affect process control or batch review?
Predictive maintenance	Estimates a rising likelihood of equipment failure from vibration, alarms, and maintenance history.	Does the alert only support planning, or does it influence continued equipment use? Are failure classes represented in training and test data?
Visual inspection support	Classifies images as likely acceptable or requiring human review.	How are images sampled and labeled? What are false-accept and false-reject rates under actual lighting, product, and line conditions?
Laboratory data review	Highlights chromatograms, microscopy images, or results that may need analyst review.	Can the analyst inspect source data? Are audit trails, method versions, and manual overrides preserved?
Quality event triage	Groups deviations or suggests relevant historical records.	Are suggestions clearly advisory? Can staff verify source records? Are omissions and invented or misranked results detectable?
Document search or drafting	Summarizes approved procedures or drafts a non-final text for review.	Is the approved source corpus controlled? Does a trained person verify every GMP-relevant statement before use or approval?
Process optimization	Suggests parameter ranges or predicts product attributes from process inputs.	Is the use within the validated process and established design space? What experiment or process evidence supports the recommendation?

Practical rule: First map where the output goes and what a person or downstream system does with it. A model can be “advisory” in a presentation but function as a control if staff routinely accept its recommendation without an independent check.

Regulatory framework: what applies today?

Pharmaceutical AI is governed through the combination of existing quality-system, GMP, computerized-system, data-integrity, and product-specific requirements that apply to the use case. AI-specific papers and draft proposals can inform a validation strategy, but their status and scope matter.

Source	Status and scope	How to use it in an AI validation program
Applicable drug GMP and quality-system requirements	Binding requirements depend on jurisdiction, product, and activity.	Use them as the compliance baseline for records, equipment, process controls, review, and quality decisions. A model does not waive existing responsibilities.
EU GMP Annex 11	The European Commission’s EudraLex index lists the published Annex 11 revision as January 2011.	Use current applicable expectations for computerized systems; confirm controlled copies, local interpretation, and current Commission status.
Proposed EU GMP Annex 22: Artificial Intelligence	Consultation draft; the consultation response period has ended, but the cited draft is not itself a final effective annex.	Use as a forward-looking design input, clearly label it as draft, and recheck for a final publication before changing compliance claims.
FDA AI drug-submission guidance	January 2025 draft guidance on AI outputs intended to support regulatory decision-making for drug and biological products.	Its risk-based credibility assessment and context-of-use concepts can inform relevant submission models. Do not describe it as final or as a general manufacturing validation rule.
FDA AI in Drug Manufacturing paper	2023 discussion paper; FDA says it is for discussion and is not draft or final guidance.	Use for awareness of issues raised for manufacturing AI and engagement, not as a binding acceptance-criteria list.
ICH Q9(R1) Quality Risk Management	International pharmaceutical quality risk-management guideline.	Use scientific, patient-focused risk analysis to determine assurance depth, with effort commensurate with risk.
FDA Computer Software Assurance guidance	FDA’s February 2026 final CSA guidance is scoped to software used in medical-device production or the device quality management system under 21 CFR Part 820.	It may offer useful risk-based testing concepts, but its stated scope should not be represented as a drug GMP AI validation regulation.

The European Commission’s consultation draft Annex 22 is especially relevant because it addresses AI models embedded in computerized systems used in GMP manufacturing, with direct impact on patient safety, product quality, or data integrity. Its proposed scope is specific: the draft describes static, deterministic machine-learning models and states that continuously adapting models, probabilistic-output models, and generative AI/large language models are outside that draft’s critical-GMP scope. Those statements describe draft text and must not be presented as current final law.

For the adopted European medicines lifecycle reflection paper, EMA provides considerations for AI from discovery through post-authorization. FDA’s 2025 draft guidance is narrower: it addresses AI models used to produce information or data supporting regulatory decisions about drug safety, effectiveness, or quality. These sources are useful, but neither replaces the site’s own GxP risk assessment and validation evidence.

Start with intended use and context of use

Before selecting metrics or test cases, write a precise intended-use statement. For each model, define the question it is allowed to answer, the data it receives, the output it provides, the users who see it, and the decisions it can influence. A vague statement such as “improves quality using AI” is not testable.

Intended-use statement template

System/model: Name, supplier, version, and deployment environment.

Purpose: The specific task and process step the model supports.

Inputs: Data types, sources, ranges, frequency, preprocessing, and required data quality.

Outputs: Prediction, classification, score, alert, summary, or recommendation and its permitted interpretation.

User and action: Who reviews the result, what decision may follow, and what independent evidence is required.

Boundaries: Products, equipment, process states, populations, languages, or data conditions that are excluded.

Failure response: Fallback process, escalation route, and conditions requiring the model to be disabled.

Keep the approved URS and intended-use statement aligned. When the use expands—for example, from maintenance planning to automated control—the risk assessment and validation scope need review before the expanded use begins.

Risk-based AI validation: assess consequence and uncertainty

Apply quality risk management across the model lifecycle, not just during initial testing. Consider potential harm from an incorrect prediction, the chance that the error will occur, the chance it will escape detection, the reversibility of the resulting action, and the uncertainty created by model complexity or limited evidence. Include both false positives and false negatives because their impact may differ.

For example, a false alert in a maintenance dashboard may create extra work, while a missed alert could allow an equipment issue to go unnoticed. A model that classifies a laboratory result or influences batch review may require stronger controls than one that only searches a controlled document repository. Use a documented CAPA path when investigation shows a quality-system deficiency, repeated model failure, or ineffective control.

Risk questions for the assessment

• Could a wrong or missing output affect product disposition, patient safety, product quality, or the completeness of a GMP record?
• Does the system directly change a process parameter, generate a result, prioritize an investigation, or only provide a suggestion?
• Can a qualified user detect a poor recommendation before acting?
• What happens if input sensors fail, a data feed is delayed, or an input falls outside the training domain?
• Can model or vendor changes occur without the site’s knowledge?
• Can records be reconstructed later, including the input, model version, output, review, and final action?

Step-by-step AI and machine learning validation lifecycle

1. Create an inventory and system boundary. Identify the model, application, data flows, interfaces, infrastructure, supplier components, users, and relevant GMP process. Decide whether each component is GxP relevant and why.
2. Assemble a cross-functional team. Include Quality, process or laboratory owners, IT/OT, data science, engineering, cybersecurity, regulatory affairs, and supplier representatives as needed. Assign system owner, model owner, process owner, approvers, and escalation contacts.
3. Approve intended use and risk assessment. Document the intended-use statement, context, boundaries, hazards, controls, residual risk, and evidence needed. Use a risk tool such as FMEA where appropriate, but explain the rationale behind severity and likelihood ratings.
4. Set requirements and acceptance criteria before testing. Define functional, data, performance, interface, security, record, and human-review requirements. Choose thresholds that reflect the use case and error consequences; do not copy a generic accuracy target.
5. Qualify data and model development controls. Record data sources, provenance, collection periods, inclusion and exclusion rules, labeling approach, preprocessing, transformations, known gaps, and controls against leakage. Document training and tuning separately from final independent testing.
6. Verify the configured system and interfaces. Test installation or deployment configuration, access controls, audit trails, calculations, units, timestamps, data transfer, failure handling, backup, restoration, and connections to validated systems. Qualification concepts such as IQ, OQ, and PQ can be adapted to the system design and documented risk.
7. Challenge model performance. Use test data independent from training and tuning. Evaluate performance across relevant products, equipment, sites, process states, and data quality conditions. Test boundary cases, missing values, outliers, noise, class imbalance, and known failure scenarios.
8. Review explainability and human factors. Show users how to interpret the output, its confidence or limitations, and when not to rely on it. Verify that workflow design supports meaningful review rather than automatic acceptance.
9. Approve release and train users. Release a controlled model and software version, configuration, thresholds, and instructions. Complete training, approvals, traceability, and any required qualification before GMP use.
10. Monitor, investigate, and control changes. Trend production performance, data drift, overrides, alerts, incidents, and complaints. Define triggers for investigation, suspension, rollback, revalidation, or change approval. Maintain a controlled SOP and periodic review process.

Data quality and independence: the foundation of model credibility

AI performance cannot be stronger than the evidence represented in its inputs and labels. A training dataset may be large yet unsuitable if it omits a product family, contains inconsistent labels, reflects only one shift or facility, or was collected with a different sensor or assay method. Evaluate whether the data match the intended population and operating conditions.

Data control	Evidence to retain	Common failure mode
Provenance and lineage	Source system, owner, collection period, extraction method, transformations, and dataset version.	Unable to trace an input back to an approved source or reproduce the model dataset.
Label quality	Labeling instructions, reviewer qualifications, adjudication rules, and disagreement rates where relevant.	Model learns inconsistent or biased labels as if they were ground truth.
Representativeness	Coverage of relevant products, process conditions, equipment, sites, seasons, shifts, and known edge cases.	High overall score hides weak performance for a critical subgroup.
Data separation	Documented train, tuning/validation, and independent test partitioning, including how related observations were separated.	Near-duplicate batches or images appear in both training and test sets, overstating performance.
Data integrity	Access permissions, audit trails, version control, retention, and correction procedures.	Silent data edits, missing metadata, or unclear ownership undermine trust in results.
Privacy and security	Approved data handling, transfer, retention, and supplier/cloud controls for sensitive or personal information.	Unapproved data are entered into a public or unmanaged AI service.

Maintain records in line with your ALCOA+ data-integrity procedures. Preserve the original data and metadata needed to reconstruct how the model reached a result. A summary score alone is not sufficient evidence when the model output is relied on for a GMP decision.

Model testing and acceptance criteria

Choose metrics that match the task. For classification, teams may consider sensitivity, specificity, precision, recall, false-accept rate, false-reject rate, and performance by subgroup. For regression, consider error distributions, bias, and fit across the validated range. For anomaly detection, assess detection delay, alert burden, and missed events. For text generation, test factual grounding, source traceability, unsafe output, omission, and whether users can verify each result.

Do not select criteria solely because they are familiar or easy to meet. Set them before final testing, tie them to risk controls and process needs, and include criteria for the system around the model: data completeness, correct routing, review completion, access control, and record retention.

Test area	Example evidence	Acceptance-criteria approach
Intended-use performance	Independent test results for the defined population and operating range.	Pre-approved limits for relevant error types and critical subgroups, justified by risk and process capability.
Robustness	Challenge tests with missing, noisy, shifted, or boundary inputs.	Defined behavior for unacceptable inputs, including warning, reject, abstain, or route-to-human review.
Repeatability	Repeated runs under controlled versions and identical inputs.	Output consistency or documented variability that remains within intended-use requirements.
Workflow and human review	Observed user testing, override cases, escalation, and final decision records.	Users can identify limitations, access source evidence, and complete the required approval step.
Integration and records	End-to-end tests from source data through model output to downstream record or decision.	Accurate transfer, unique identity, timestamps, audit-trail capture, and recoverable records.
Security and resilience	Access, backup/restore, vendor update, incident, and business-continuity testing.	Critical failures are prevented or detected, escalated, and recoverable within approved procedures.

No universal numerical threshold: Regulations do not provide one accuracy percentage that makes every pharma AI model acceptable. Set site-specific criteria based on intended use, error consequences, data characteristics, human controls, and applicable product or process requirements. Report uncertainty and limitations, not only a headline accuracy figure.

Special considerations for generative AI and large language models

Generative AI can draft, summarize, classify, retrieve, or transform text, but it may produce unsupported statements, omit relevant information, or change behavior when prompts, source documents, model versions, or retrieval settings change. Treat each use as a defined computerized-system function with controlled inputs, outputs, review, and records.

• Prefer approved, access-controlled source content for retrieval and provide traceable citations or document references in outputs where feasible.
• Test representative prompts, ambiguous requests, conflicting sources, missing evidence, and attempts to elicit unsupported instructions.
• Make the status of a generated draft clear; require qualified personnel to verify GMP-relevant content before approval or execution.
• Record the model/service version, prompt or configuration where relevant, source set, generated output, reviewer changes, and final decision when needed for reconstruction.
• Prevent confidential, personal, or regulated information from being sent to unapproved public services. Assess retention, provider access, location, and security terms.
• Control provider model updates, retrieval-index changes, plug-ins, connected tools, and prompts through change assessment and testing.

The EU consultation draft Annex 22 specifically excludes generative AI and LLMs from its proposed critical GMP scope and describes a human-in-the-loop expectation for non-critical GMP use. This is draft language, not an adopted blanket prohibition. It is a useful signal to evaluate whether a proposed critical application can be controlled and justified under current requirements while regulators finalize their approach.

Deployment, monitoring, and model change control

Lock the approved model artifact and supporting configuration at release. Record the model identifier, software and library versions, preprocessing steps, thresholds, feature definitions, runtime environment, data interfaces, and approval date. Ensure the released configuration matches the one tested.

Define monitoring before go-live. Depending on the model, monitor input completeness and range, prediction distributions, error rates against confirmed outcomes, data drift, alert rates, reviewer overrides, user complaints, and process outcomes. A change in input instruments, assay methods, supplier datasets, products, operating ranges, or user workflows can affect performance even when the model code is unchanged.

Change triggers that should prompt assessment

• Model retraining, fine-tuning, replacement, threshold adjustment, or architecture change.
• New or revised training data, labels, preprocessing, feature engineering, or data pipeline.
• Changes to sensors, instruments, manufacturing equipment, laboratory methods, or source systems.
• New product, site, process range, user group, language, or intended use.
• Supplier, hosting, cloud region, security, storage, or service-level change.
• Performance drift, repeated overrides, unexplained output, incident, deviation, or relevant CAPA.

Use impact assessment to choose regression testing, partial revalidation, or full revalidation. The decision should be justified and approved before the changed model is used in a regulated process. A dynamic model that learns automatically after deployment needs especially careful governance; do not allow unreviewed changes to alter a GMP decision path.

Supplier and cloud AI oversight

When a vendor supplies a model, platform, managed service, or data pipeline, the regulated company remains accountable for the system’s use in its quality process. Assess the provider’s development and change controls, security, data handling, incident notification, audit support, model update policy, performance evidence, and service continuity. Obtain sufficient documentation to support your own risk assessment and validation conclusions.

For cloud and SaaS deployments, include tenant configuration, access control, backup and restore, data location and retention, provider release cadence, interfaces, disaster recovery, and exit or data-export arrangements. Vendor qualification can support your work, but does not automatically validate the configured use at your site.

Documentation package: what should the validation file contain?

• AI/model inventory entry and GxP impact assessment
• Intended use, boundaries, user roles, and workflow map
• Quality risk assessment and control rationale
• Approved requirements and traceability matrix
• Supplier assessment and service agreements
• Data provenance, preparation, labeling, and version records
• Model development and configuration documentation
• Pre-approved test plan and acceptance criteria
• Independent test results, deviations, and resolution
• Installation, integration, security, and recovery evidence
• Training materials and user qualification records
• Release approval, limitations, and operating instructions
• Monitoring plan, thresholds, periodic review, and drift response
• Change control, retraining, incident, rollback, and retirement records
• Data-retention and reconstruction strategy for regulated decisions

Maintain trustworthy, attributable records for model decisions and their review. Your approved SOP set should explain how teams perform risk assessment, testing, release, monitoring, periodic review, and change control. Document and investigate validation or operational failures through the quality system, including CAPA when appropriate.

Common AI validation mistakes and how to prevent them

Mistake	Why it weakens control	Better practice
Validating only the model score	Ignores input data, interfaces, workflow, review, security, and record controls.	Validate the complete configured system and intended process.
Using training data as the final test set	Produces optimistic performance and hides generalization errors.	Keep a documented independent test set and prevent leakage.
Using one overall accuracy number	Can conceal failure in a critical class, product, site, or condition.	Report error types and performance for risk-relevant subgroups and ranges.
Leaving “human in the loop” undefined	A nominal reviewer may simply accept model output without meaningful verification.	Define reviewer competence, evidence to check, override authority, and recorded rationale.
Allowing uncontrolled auto-learning	Behavior may change without approved testing or traceability.	Control retraining and deployment as changes; monitor and approve each model version.
Assuming vendor testing equals site validation	The site’s data, configuration, process, and users may differ from the vendor’s test context.	Use supplier evidence as an input, then verify the actual configured intended use.
Calling a draft guidance “the requirement”	Confuses a consultation document with current binding or adopted requirements.	Track source status and distinguish laws, final guidance, reflection papers, and proposals.

Example: validating an AI model for process anomaly alerts

Assume a model analyzes historian data to flag unusual temperature and pressure patterns for an operator’s review. The intended use is to identify possible excursions early; the model does not change setpoints or release a batch.

1. Define boundaries: Identify the equipment train, products, process phases, sensors, operating ranges, excluded states, and personnel who receive alerts.
2. Assess risk: Evaluate a missed alert, false alarm, delayed data, sensor failure, and incorrect time alignment. Determine what independent controls already detect excursions.
3. Build representative test evidence: Include confirmed historical events, normal operation, known nuisance patterns, instrument issues, and challenging but plausible operating conditions.
4. Set criteria: Predefine acceptable detection behavior and false-alert burden in the context of process needs; specify what the model must do when data are missing or outside range.
5. Verify workflow: Ensure alerts reach the correct operator, include relevant context, are acknowledged, and result in a documented investigation when required.
6. Monitor after release: Trend alert rate, confirmed events, misses found through independent review, user overrides, sensor changes, and model performance by process phase.
7. Control changes: Assess new product use, revised sensor calibration, new data, retraining, or threshold updates through change control before deployment.

This example shows why validation is more than a benchmark. The operational procedure, alarm routing, investigation process, and human response are part of the controlled use.

Roles and responsibilities

Role	Typical responsibility
Quality Assurance	Approves risk-based strategy, criteria, deviations, release, and lifecycle procedures; confirms the quality system remains effective.
Process or laboratory owner	Defines the business and GMP use, users, process boundaries, relevant failure modes, and meaningful acceptance criteria.
Model/data science team	Documents data and model methods, development controls, performance analyses, limitations, and reproducibility evidence.
IT/OT and system owner	Controls infrastructure, identity, interfaces, security, backup, deployment configuration, and technical change management.
Supplier or service provider	Provides agreed technical, quality, security, change, incident, and performance information for the supplied service or model.
Trained end user	Uses model outputs only within approved boundaries, performs required checks, records decisions, and escalates unexpected behavior.

Related pharmaceutical validation guides

Computerized System ValidationRisk-based lifecycle controls for GxP software. ALCOA+ Data IntegrityPrinciples for trustworthy records and evidence. 21 CFR Regulations for PharmaceuticalsElectronic records and regulated system context. CAPA in PharmaceuticalsInvestigating causes and preventing recurrence.

Frequently asked questions about AI validation in pharma

1. What is AI and machine learning validation in pharma?

It is documented evidence that an AI-enabled system performs its defined function for an approved pharmaceutical use, with suitable controls over data, software, model behavior, users, records, monitoring, and changes.

2. Does every AI tool used by a pharma company need GxP validation?

No universal answer applies to every tool. Assess its intended use and whether it supports or affects a regulated activity, product quality, patient safety, or a GMP record. Document the rationale and controls, including for tools judged non-GxP.

3. What is the difference between model validation and system validation?

Model validation evaluates whether the model meets its performance requirements for its intended use. System validation also covers the configured application, data pipelines, interfaces, infrastructure, access, audit trails, human workflow, records, and lifecycle controls.

4. What does intended use mean for an AI model?

It defines the task, inputs, outputs, users, operating conditions, decision influence, limitations, and excluded applications. Acceptance criteria and test data should match this defined context.

5. How should training and test data be separated?

Keep final test data independent from model training and tuning. Document partitioning and prevent leakage, including leakage from duplicate or closely related batches, images, time series, or records.

6. Is there a universal accuracy threshold for a validated pharma AI model?

No. Acceptance criteria should be justified for the model’s use and risk. Relevant measures may include false positives, false negatives, subgroup performance, uncertainty, robustness, and workflow behavior, not only overall accuracy.

7. Can a machine-learning model retrain itself after deployment?

Automatic retraining can change model behavior and requires strong governance. Define how updates are detected, assessed, tested, approved, and documented. Uncontrolled learning should not alter a GMP process or decision path.

8. Can generative AI be used for GMP documentation?

It may assist with bounded, non-final tasks when the use is assessed and controlled. Use approved sources, protect confidential data, preserve traceability where needed, and require trained personnel to verify GMP-relevant output before approval or use.

9. Is the proposed EU GMP Annex 22 currently an effective requirement?

The European Commission consultation draft is not itself a final effective annex. The published EudraLex index should be checked for the latest adopted text and implementation date before making compliance decisions.

10. Does FDA’s AI guidance apply to all pharmaceutical manufacturing AI?

FDA’s January 2025 draft guidance focuses on AI information or data intended to support regulatory decision-making about drug and biological products. FDA’s 2023 AI in Drug Manufacturing paper is a discussion paper, not draft or final guidance. Neither should be described as a universal manufacturing validation rule.

11. What should be monitored after AI deployment?

Monitor measures relevant to the use, such as input quality, performance against confirmed outcomes, drift, alert volume, user overrides, incidents, data source changes, and process outcomes. Establish thresholds and response actions in advance.

12. Who is ultimately responsible for a vendor-provided AI model?

The regulated company remains responsible for its GMP use. Supplier evidence can support qualification and validation, but the company must assess the configured service, its intended use, local data, interfaces, users, and ongoing controls.

Official references and further reading

1. European Commission — EudraLex Volume 4 (current published GMP chapters and annexes, including Annex 11 status).
2. European Commission — Stakeholder consultation on revised Chapter 4, Annex 11, and proposed Annex 22.
3. European Commission — Consultation draft Annex 22: Artificial Intelligence (draft document; check for final publication).
4. EMA — Reflection paper on the use of AI in the medicinal product lifecycle (adopted version and document history).
5. FDA — Considerations for the Use of AI to Support Regulatory Decision-Making for Drug and Biological Products (January 2025 draft guidance).
6. FDA — Artificial Intelligence in Drug Manufacturing (2023 discussion paper; not draft or final guidance).
7. ICH Q9(R1) — Quality Risk Management.
8. FDA — Computer Software Assurance for Production and Quality Management System Software (February 2026; medical-device production and QMS scope).
9. FDA — Data Integrity and Compliance With Drug CGMP: Questions and Answers.

Build an evidence-based AI lifecycle

AI and machine learning can support pharmaceutical work when the intended use is clear, the data and model are appropriate for that use, and the complete workflow remains under effective quality-system control. Define the risk, test the right failure modes, preserve the evidence, and monitor whether the system continues to perform as expected.

Educational overview for pharmaceutical quality, validation, engineering, laboratory, and digital teams. It is not a substitute for applicable regulations, current regulator publications, professional judgment, or a site-specific validation strategy. Confirm regulatory status and approved procedures before implementing an AI use in a GMP process.